<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5855">
  <stage>Registered</stage>
  <submitdate>9/03/2016</submitdate>
  <approvaldate>9/03/2016</approvaldate>
  <nctid>NCT02716428</nctid>
  <trial_identification>
    <studytitle>A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection</studytitle>
    <scientifictitle>A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TRK-450-0203</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C Viral Infection</healthcondition>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <healthcondition>Hepatitis C (HCV)</healthcondition>
    <healthcondition>Hepatitis C Genotype 1</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Faldaprevir
Treatment: drugs - TD-6450
Treatment: drugs - Ribavirin

Experimental: Cohort 1 - 12 weeks of Faldaprevir plus TD-6450 plus Ribavirin

Experimental: Cohort 2 - 12 weeks of Faldaprevir plus TD-6450


Treatment: drugs: Faldaprevir


Treatment: drugs: TD-6450


Treatment: drugs: Ribavirin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of subjects achieving 12-week sustained virologic response following treatment with 2 direct acting anti-virals with and without ribavirin in Genotype 1b Hepatitis C infected adults</outcome>
      <timepoint>Post Treatment Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with virologic response 2, 4 and 8 weeks after treatment completion (HCV RNA less than lower limit of quantitation at 2, 4 and 8 weeks after end of therapy with Faldaprevir plus TD-6450 with and without ribavirin)</outcome>
      <timepoint>Post Treatment Weeks 2 to 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety as determined by the incidence of serious adverse events, Grade 3 or 4 adverse events and laboratory abnormalities, and discontinuations due to adverse events</outcome>
      <timepoint>Randomization through End of Study, up to 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Chronic genotype 1b hepatitis C infection and HCV RNA = 10^4 IU/mL at screening

          -  Hepatitis C virus treatment naive, defined as defined as having never received a
             direct acting anti-viral (DAA), and as having received = 8 weeks of interferon = 6
             months prior to screening

          -  Absence of cirrhosis as defined by one of the following:

               -  A liver biopsy performed within 24 calendar months of Day 1 showing absence of
                  cirrhosis

               -  Transient elastography (FibroScan®) performed within 12 calendar months of Day 1
                  with a result of = 12.5 kPa (kilopascals)

               -  A non-invasive test measuring liver scarring (FibroSure®) score = 0.48 and AST
                  (aspartate aminotransferase):platelet ratio (APRI) = 1 performed during screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Infection with hepatitis B virus (HBV) or human immunodeficiency virus, HIV-1 or HIV-2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Trek Therapeutics, PBC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir
      and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in
      treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02716428</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ed Gane, MD</name>
      <address>Auckland Clinical Studies Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>